Glaukos' Epioxa Shows Durable Benefits At Three Years In Keratoconus Study
Glaukos (GKOS) reported positive three-year data from a Phase 3 extension study of Epioxa, its corneal cross-linking therapy for keratoconus. The study showed durable efficacy and a favorable safety profile, with treated eyes showing sustained improvement in corneal curvature and visual acuity. GKOS reported a narrowed net loss and 50% sales growth in Q2 2026, with 2026 net sales guidance of $680M-$700M. The stock is up 6.55% on the day.
How this was made
The 30-second read
Why it matters
The three‑year extension data provide the first long‑term efficacy and safety evidence, a key catalyst for valuation and market positioning.
Market read
Positive long‑term trial outcomes are likely to lift GKOS and may positively influence the broader ophthalmic biotech sector.
What to watch
Potential competition from other epi‑on cross‑linking technologies and the need for broader commercial uptake.
Background
Glaukos (GKOS) is a U.S. ophthalmic pharmaceutical company with an FDA‑approved epi‑on corneal cross‑linking product, Epioxa, launched in Oct 2025.
Ticker impact
Glaukos reported three‑year Phase 3 extension data showing durable efficacy and safety of its Epioxa corneal cross‑linking therapy.
likely upward pressure as the market prices in durable efficacy and safety data.
The data are the first disclosure of three‑year outcomes, a material clinical milestone for a biotech with an FDA‑approved product.
Market effects
Strengthens the ophthalmic biotech segment and may lift peers developing corneal therapies.
U.S. biotech market could see modest gains from the positive data.
Highlights continued innovation in non‑invasive eye treatments, relevant to global ophthalmology investors.
Counterpoint
If longer‑term safety concerns emerge or reimbursement remains limited, the rally could be muted.
Key entities
- CompanyGlaukos Corporation
U.S. ophthalmic biotech that developed Epioxa.
- ExecutiveThomas Burns
Chairman and CEO of Glaukos, quoted on the trial results.
